Enhanced CDC of B cell chronic lymphocytic leukemia cells mediated by rituximab combined with a novel anti-complement factor H antibody.

PLoS One · 2017 · PMC5489178 · PMID 28658265

Europe PMC DOI

hedged sentence

0.1600

closest p · 3.2× alpha

0.1600

boldest claim

The sentences

failed to reach statistical significancep = 0.16not close (p > 0.1)

However, when rituximab and the CFH mAb were added together, CDC of the B-CLL cells of this patient increased nearly two-fold over background ( Fig 1B ) although this effect failed to reach statistical significance (p = 0.16).

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.